Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA
<h4>Background and Aims</h4> <p>Randomised trials have described the benefits of adalimumab [ADA] for ulcerative colitis [UC]; however, few data are available on health-related quality of life [HRQL] and health care costs in clinical practice.</p> <h4>Methods</h4>...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Oxford University Press
2017
|
| _version_ | 1797069401141280768 |
|---|---|
| author | Travis, S Feagan, BG Peyrin-Biroulet, L Panaccione, R Danese, S Lazar, A Robinson, AM Petersson, J Pappalardo, BL Bereswill, M Chen, N Wang, S Skup, M Thakkar, RB Chao, J |
| author_facet | Travis, S Feagan, BG Peyrin-Biroulet, L Panaccione, R Danese, S Lazar, A Robinson, AM Petersson, J Pappalardo, BL Bereswill, M Chen, N Wang, S Skup, M Thakkar, RB Chao, J |
| author_sort | Travis, S |
| collection | OXFORD |
| description | <h4>Background and Aims</h4> <p>Randomised trials have described the benefits of adalimumab [ADA] for ulcerative colitis [UC]; however, few data are available on health-related quality of life [HRQL] and health care costs in clinical practice.</p> <h4>Methods</h4> <p>InspirADA, a multicentre, prospective study, evaluated the effect of ADA in patients with moderate to severe UC treated according to usual clinical practice. Outcomes assessed were: Simple Clinical Colitis Activity Index [SCCAI] response/remission rates; changes in HRQL; all-cause direct costs; and UC-related direct and indirect costs from baseline to Week 26.</p> <h4>Results</h4> <p>Data from 463 patients were analysed. At Week 26, 67% (95% confidence interval [CI]: 62%, 71%) of patients achieved response; 48% [95% CI: 44%, 53%] were in remission. For the overall population, significant [all p < 0.001] improvements from baseline to Week 26 were observed for the Short Inflammatory Bowel Disease Questionnaire [SIBDQ] (mean change ± standard deviation [SD]: 17.4 ± 14.5) and the European Quality of Life—5 Dimensions—5 Level [EQ-5D-5L] (index: 0.1 ± 0.2; visual analogue scale [VAS]: 19.5 ± 25.8). Parallel improvements were seen in work productivity [11% absolute decrease in absenteeism; 25% absolute decrease in impairment while working; and 27% absolute decrease in impairment of ability to perform daily activities, all p < 0.001]. Among study completers, cumulative all-cause medical costs and UC-related medical costs were significantly [both p < 0.001] reduced by 59% and 77%, respectively, 6 months after initiation of therapy compared with the preceding 6 months. The safety profile of ADA was consistent with that observed in previous clinical trials.</p> <h4>Conclusions</h4> <p>ADA therapy in usual clinical practice is effective at improving and maintaining symptomatic control, improving HRQL, and decreasing costs of medical care among patients with UC.</p> |
| first_indexed | 2024-03-06T22:23:54Z |
| format | Journal article |
| id | oxford-uuid:56016f07-b0da-40f4-8b62-4a1d741e26f4 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T22:23:54Z |
| publishDate | 2017 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:56016f07-b0da-40f4-8b62-4a1d741e26f42022-03-26T16:47:41ZEffect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADAJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:56016f07-b0da-40f4-8b62-4a1d741e26f4Symplectic Elements at OxfordOxford University Press2017Travis, SFeagan, BGPeyrin-Biroulet, LPanaccione, RDanese, SLazar, ARobinson, AMPetersson, JPappalardo, BLBereswill, MChen, NWang, SSkup, MThakkar, RBChao, J <h4>Background and Aims</h4> <p>Randomised trials have described the benefits of adalimumab [ADA] for ulcerative colitis [UC]; however, few data are available on health-related quality of life [HRQL] and health care costs in clinical practice.</p> <h4>Methods</h4> <p>InspirADA, a multicentre, prospective study, evaluated the effect of ADA in patients with moderate to severe UC treated according to usual clinical practice. Outcomes assessed were: Simple Clinical Colitis Activity Index [SCCAI] response/remission rates; changes in HRQL; all-cause direct costs; and UC-related direct and indirect costs from baseline to Week 26.</p> <h4>Results</h4> <p>Data from 463 patients were analysed. At Week 26, 67% (95% confidence interval [CI]: 62%, 71%) of patients achieved response; 48% [95% CI: 44%, 53%] were in remission. For the overall population, significant [all p < 0.001] improvements from baseline to Week 26 were observed for the Short Inflammatory Bowel Disease Questionnaire [SIBDQ] (mean change ± standard deviation [SD]: 17.4 ± 14.5) and the European Quality of Life—5 Dimensions—5 Level [EQ-5D-5L] (index: 0.1 ± 0.2; visual analogue scale [VAS]: 19.5 ± 25.8). Parallel improvements were seen in work productivity [11% absolute decrease in absenteeism; 25% absolute decrease in impairment while working; and 27% absolute decrease in impairment of ability to perform daily activities, all p < 0.001]. Among study completers, cumulative all-cause medical costs and UC-related medical costs were significantly [both p < 0.001] reduced by 59% and 77%, respectively, 6 months after initiation of therapy compared with the preceding 6 months. The safety profile of ADA was consistent with that observed in previous clinical trials.</p> <h4>Conclusions</h4> <p>ADA therapy in usual clinical practice is effective at improving and maintaining symptomatic control, improving HRQL, and decreasing costs of medical care among patients with UC.</p> |
| spellingShingle | Travis, S Feagan, BG Peyrin-Biroulet, L Panaccione, R Danese, S Lazar, A Robinson, AM Petersson, J Pappalardo, BL Bereswill, M Chen, N Wang, S Skup, M Thakkar, RB Chao, J Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA |
| title | Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA |
| title_full | Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA |
| title_fullStr | Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA |
| title_full_unstemmed | Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA |
| title_short | Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: Results from inspirADA |
| title_sort | effect of adalimumab on clinical outcomes and health related quality of life among patients with ulcerative colitis in a clinical practice setting results from inspirada |
| work_keys_str_mv | AT traviss effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT feaganbg effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT peyrinbirouletl effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT panaccioner effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT daneses effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT lazara effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT robinsonam effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT peterssonj effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT pappalardobl effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT bereswillm effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT chenn effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT wangs effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT skupm effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT thakkarrb effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada AT chaoj effectofadalimumabonclinicaloutcomesandhealthrelatedqualityoflifeamongpatientswithulcerativecolitisinaclinicalpracticesettingresultsfrominspirada |